Application of alpha-mangostin to preparation of medicine for treating autoimmune disease

An autoimmune disease, mangostin technology, applied in skin diseases, bone diseases, drug combinations, etc., can solve the problems of weakening clinical symptoms, not finding target drugs, poor selectivity, etc., and achieve the effect of inhibiting Th17 cell activity

Inactive Publication Date: 2017-08-08
SUN YAT SEN UNIV
View PDF2 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, the natural ligand of RORγt has not been found, but two recent studies found that the synthetic molecule digoxin and its derivatives (Huh et al., 20011; Fujita-Sato et al., 2011) and SR1001 (Solt et al .,2011) can specifically bind to the ligand domain of RORγt, inhibit the function of RORγt and reduce the differentiation ability of Th17 cells, attenuating the clinical symptoms of mouse autoimmune disease EAE
However, digoxin and its derivatives are highly toxic (Paula et al., 2005); although SR1001 molecule can effectively inhibit the differentiation of Th17 cells in vitro, it cannot be administered at a high concentration (40mg / kg) in vivo. , can only slightly alleviate the clinical symptoms of EAE
In addition, SR1001 can interact with other RORs with poor selectivity (Solt et al., 2011)
On the one hand, these studies show that inhibiting the function of RORγt to treat autoimmune diseases is a feasible solution, but an ideal target drug has not yet been found

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of alpha-mangostin to preparation of medicine for treating autoimmune disease
  • Application of alpha-mangostin to preparation of medicine for treating autoimmune disease
  • Application of alpha-mangostin to preparation of medicine for treating autoimmune disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0021] In order to better illustrate the purpose, technical solutions and advantages of the present invention, the present invention will be further described below in conjunction with specific embodiments and accompanying drawings.

[0022] Reagent source

[0023] The cell line Jurkat was preserved in our laboratory; the bacterial strain DH5α was donated by Professor Ma Runlin, Institute of Genetics, Chinese Academy of Sciences, Beijing; the restriction endonuclease was purchased from Fermentas Company of the United States; the DNA ligase was purchased from NEB Company of the United States; the reporter gene sequence IRES-GFP was the inventor Self-preservation (other existing reporter gene sequences can also be used); reporter plasmid pGL4.31[luc2P / GAL4UAS / Hygro] and pBIND plasmid were purchased from Promega Company in the United States; DMEM medium and RPMI1640 medium and acetone for culturing cells Sodium phosphate, glutamine, β-mercaptoethanol, non-essential amino acids, a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of alpha-mangostin to preparation of medicine for treating autoimmune disease. As proved by researches, the alpha-mangostin can be taken as an inhibitor of Th17 cell activity, and can be used for inhibiting differentiation and formation of Th17 cells.

Description

technical field [0001] The invention relates to a new application of α-mangostin, in particular to the application of α-mangostin in the preparation of medicines for treating autoimmune diseases. Background technique [0002] About 5% of the population suffers from autoimmune diseases, and more than 70 human diseases are related to autoimmune disorders (Goodnow et al., 2005). At present, the treatment of autoimmune diseases mainly relies on some non-selective immunosuppressants, which have limited curative effect and large side effects. There is no very effective drug for the treatment of autoimmune diseases in clinical practice. Therefore, there is an urgent need to develop a new type of autoimmune drug with high efficacy and low side effects. [0003] The latest research shows that Th17 cells, a new T cell subset, are closely related to the occurrence of human autoimmune diseases and related animal models (Kikly et al., 2006). In autoimmune diseases such as rheumatoid ar...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61P37/02A61P17/06A61P29/00A61P19/02A61P17/00A61P11/00A61P1/00
CPCA61K31/352
Inventor 黄朝峰何细新柏川陈焕鹏周晓庆
Owner SUN YAT SEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap